[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6154 followers
Created: 2025-07-25 17:38:39 UTC

Aarti Drugs Expands Capacity & Eyes Growth 🚀 Key Updates on Revenue, Margins & Sustainability | MCap XXXXXXXX Cr

- Revenue grew X% YoY to ₹591 Cr in Q1 FY26, with EBITDA up XX% to ₹74 Cr.
- Gross margins improved by XXX bps to 36.8%, with further gains expected from H2 FY26.
- API business grew X% YoY, while formulations surged XX% (₹80 Cr, XX% exports).
- Salicylic acid capacity expansion underway (target: XXXXX MT/month at Tarapur).
- Greenfield project in Sayakha, Gujarat, begins trial production (anti-diabetic focus).
- USFDA & UK MHRA approvals secured, boosting regulated market presence.
- Formulation business aims to double to ₹550-600 Cr in X years (oncology & exports).
- Capex of ₹48.5 Cr in Q1; full-year guidance at ₹150-200 Cr.
- Leveraging US tariffs on Chinese APIs for market expansion.
- XXXX MW solar project underway to cut costs & carbon footprint.
- Debt stable at ₹597 Cr (D/E ratio: 0.42-0.43).
- Targets XX% volume CAGR over X years, with Chinese competition in salicylic acid.

Complete Source:

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

Preview 👇 (First X out of XX pages)

![](https://pbs.twimg.com/media/GwuHMGKXQAAX8Nn.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948800076387627257/c:line.svg)

**Related Topics**
[h2](/topic/h2)
[mcap](/topic/mcap)
[sustainability](/topic/sustainability)
[drugs](/topic/drugs)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1948800076387627257)